tiprankstipranks
Trending News
More News >
Pluri (PLUR)
NASDAQ:PLUR
Advertisement

Pluri (PLUR) AI Stock Analysis

Compare
970 Followers

Top Page

PLUR

Pluri

(NASDAQ:PLUR)

Rating:49Neutral
Price Target:
$5.00
▼(-3.10%Downside)
Pluri's overall stock score is primarily impacted by its weak financial performance, characterized by significant losses and high leverage. While technical indicators suggest some positive momentum, the negative valuation metrics and lack of profitability weigh heavily on the score. The recent corporate event of regaining Nasdaq compliance is positive but does not significantly alter the overall risk profile.

Pluri (PLUR) vs. SPDR S&P 500 ETF (SPY)

Pluri Business Overview & Revenue Model

Company DescriptionPluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
How the Company Makes MoneyPluri generates revenue primarily through the sale of its software solutions and platform subscriptions. The company offers various pricing tiers, enabling it to cater to both small businesses and large enterprises. Additionally, Pluri forms strategic partnerships with other technology providers to enhance its product offerings and expand its market reach, which also contributes to its revenue streams. The company's earnings are further supported by consulting and support services provided to its clients, ensuring successful implementation and ongoing utilization of its software solutions.

Pluri Financial Statement Overview

Summary
Pluri faces significant financial challenges, with ongoing losses and high leverage. While revenue growth is a positive sign, the company's profitability and cash flow issues pose substantial risks. The high debt levels and minimal equity raise concerns about financial stability and the ability to sustain operations without additional financing.
Income Statement
35
Negative
Pluri's income statement shows a consistent increase in revenue over the years, with a notable growth rate of 13.57% from 2023 to 2024. However, the company continues to incur significant losses, as evidenced by negative EBIT and net income margins. The gross profit margin is high at 98.77% for 2024, but this is overshadowed by the substantial operating losses, indicating challenges in achieving profitability.
Balance Sheet
25
Negative
The balance sheet reveals a precarious financial position, with a very high debt-to-equity ratio due to minimal stockholders' equity. The equity ratio has drastically declined to 0.24% in 2024, reflecting high leverage and potential solvency risks. Return on equity is negative, further indicating financial instability and challenges in generating returns for shareholders.
Cash Flow
40
Negative
Pluri's cash flow statement highlights ongoing cash flow challenges, with negative operating and free cash flows. The free cash flow growth rate improved slightly from 2023 to 2024, but remains negative, indicating continued cash burn. The operating cash flow to net income ratio is positive, suggesting some efficiency in managing cash relative to net losses.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue326.00K287.00K234.00K0.0023.00K
Gross Profit322.00K278.00K-41.36M-50.62M-1.55M
EBITDA-20.23M-27.68M-39.43M-48.42M-27.91M
Net Income-20.89M-28.32M-41.02M-49.87M-29.35M
Balance Sheet
Total Assets39.53M50.80M68.06M93.54M65.53M
Cash, Cash Equivalents and Short-Term Investments30.24M40.17M55.02M64.95M45.78M
Total Debt29.61M29.91M28.80M24.58M1.58M
Total Liabilities34.11M35.50M35.88M36.39M9.43M
Stockholders Equity96.00K13.36M30.04M57.15M56.10M
Cash Flow
Free Cash Flow-18.34M-23.12M-36.78M-31.28M-26.64M
Operating Cash Flow-18.02M-22.86M-36.50M-30.91M-26.37M
Investing Cash Flow10.58M9.70M11.78M-7.26M-30.46M
Financing Cash Flow8.84M8.02M7.50M61.40M60.87M

Pluri Technical Analysis

Technical Analysis Sentiment
Positive
Last Price5.16
Price Trends
50DMA
4.89
Positive
100DMA
4.75
Positive
200DMA
4.72
Positive
Market Momentum
MACD
0.07
Positive
RSI
50.55
Neutral
STOCH
52.12
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PLUR, the sentiment is Positive. The current price of 5.16 is below the 20-day moving average (MA) of 5.27, above the 50-day MA of 4.89, and above the 200-day MA of 4.72, indicating a neutral trend. The MACD of 0.07 indicates Positive momentum. The RSI at 50.55 is Neutral, neither overbought nor oversold. The STOCH value of 52.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PLUR.

Pluri Risk Analysis

Pluri disclosed 42 risk factors in its most recent earnings report. Pluri reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Pluri Peers Comparison

Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
HK$16.95B6.14-7.34%3.69%12.24%-25.44%
50
Neutral
$31.35M-1738.36%-43.55%69.81%
50
Neutral
$21.42M597.53%88.13%92.45%
49
Neutral
$41.43M-1205.58%203.23%13.57%
41
Neutral
$23.59M-24.97%38.80%
39
Underperform
$30.61M-282.07%-220.54%
30
Underperform
$43.18M-2880.11%31.09%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PLUR
Pluri
5.16
-0.49
-8.67%
TPST
Tempest Therapeutics
7.49
-13.05
-63.53%
DARE
Daré Bioscience
2.42
-0.90
-27.11%
CLNN
Clene
3.49
-0.84
-19.40%
NRSN
Neurosense Therapeutics Ltd.
1.08
0.34
45.95%
GDTC
CytoMed Therapeutics Limited
1.83
0.06
3.39%

Pluri Corporate Events

Executive/Board ChangesPrivate Placements and FinancingShareholder Meetings
Pluri’s 2025 Annual Meeting Decisions Announced
Neutral
Jul 3, 2025

On June 30, 2025, Pluri held its 2025 Annual Meeting where shareholders voted on several proposals. Key decisions included the election of directors, ratification of the accounting firm Kesselman & Kesselman, approval of the 2016 Equity Compensation Plan, and the determination that future advisory votes on executive compensation will occur every two years. Additionally, the approval of the exercise of warrants related to a private placement offering was confirmed, excluding shares owned by Mr. Alexandre Weinstein.

The most recent analyst rating on (PLUR) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Pluri stock, see the PLUR Stock Forecast page.

Delistings and Listing ChangesRegulatory Filings and Compliance
Pluri Regains Nasdaq Compliance Before Deadline
Positive
May 8, 2025

Pluri Inc. received a deficiency letter from Nasdaq on November 25, 2024, for not meeting the stockholders’ equity requirement or alternative listing standards. After submitting a compliance plan, Nasdaq granted an extension until May 24, 2025. By May 7, 2025, Pluri regained compliance by maintaining a market value of $35 million for 10 consecutive days, ensuring its continued listing on The Nasdaq Capital Market.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 28, 2025